http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Andrea Giannini (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
( Riccardo Zucchini ),( Andrea Sambri ),( Michele Fiore ),( Claudio Giannini ),( Davide Maria Donati ),( Massimiliano De Paolis ) 대한고관절학회 2021 Hip and Pelvis Vol.33 No.3
Purpose: Reconstruction of the proximal femur after tumour resection can be performed with proximal femoral endopros-theses (PFE). Many studies have reported that bipolar hemiarthroplasty (BHA) reduce the risk of dislocation after oncological resections. However, progressive cotyloiditis which might require acetabular resurfacing (total hip arthroplasty [THA]) has been reported. The aim of this study is to compare the results of BHA and THA after proximal femur resection. Materials and Methods: A total of 104 consecutive patients affected by primary (n=52) and metastatic (n=52) bone tumours were included. Ninety patients underwent BHA and 14 patients underwent THA. Complications were recorded and classified according to the Henderson classification. At final follow-up, patients with the implant in site were functionally evaluated with modified Harris hip score (HHS). Results: The mean follow-up was 50 months (range, 2-171 months). Twenty-four (23.1%) patients developed major complications. Eleven (12.2%) BHA required acetabular resurfacing. Patients affected by primary bone tumours showed an increased risk of THA conversion (P=0.042). A reduced risk was observed in patients younger than 35 years (P=0.043) and in those older than 65 years (P=0.033). Dislocation occurred in four case (3.8%), in particular after THA (P=0.021). At final follow-up, 93 patients had the prosthesis in site (80 BHA and 13 THA). Mean postoperative HHS was 70 (range, 30-90). Conclusion: The risk of dislocation is lower for bipolar endoprosthesis compared to THA. However cotyloiditis and acetabular resurfacing might occurred.
-
Sentinel node mapping in endometrial cancer
Giorgio Bogani,Andrea Giannini,Enrico Vizza,Francesco Raspagliesi,Violante Di Donato 대한부인종양학회 2024 Journal of Gynecologic Oncology Vol.35 No.1
Nodal status is one of the most important prognostic factors for patients with apparentearly stage endometrial cancer. The role of retroperitoneal staging in endometrial cancer iscontroversial. Nodal status provides useful prognostic data, and allows to tailor the needof postoperative treatments. However, two independent randomized trials showed thatthe execution of (pelvic) lymphadenectomy increases the risk of having surger y-relatedcomplication without improving patients’ outcomes. Sentinel node mapping aims toachieve data regarding nodal status without increasing morbidity. Sentinel node mappingis the removal of first (clinically negative) lymph nodes draining the uterus. Several studiessuggested that sentinel node mapping is not inferior to lymphadenectomy in identif yingpatients with nodal disease. More importantly, thorough ultrastaging sentinel node mappingallows the detection of low volume disease (micrometastases and isolated tumor cells), thatare not always detectable via conventional pathological examination. Therefore, the adoptionof sentinel node mapping guarantees a higher identification of patients with nodal diseasethan lymphadenectomy. Further evidence is needed to assess the value of various adjuvantstrategies in patients with low volume disease and to tailor those treatments also on the basisof the molecular and genomic characterization of endometrial tumors.
-
Patrizia Saccucci,Alberto Verrotti,Cosimo Giannini,Marcello Verini,Francesco Chiarelli,Anna Neri,Andrea Magrini 대한천식알레르기학회 2014 Allergy, Asthma & Immunology Research Vol.6 No.3
Several lines of evidence are implicating an increased persistence of apoptotic cells in patients with asthma. This is largely due to a combination ofinhibition, or defects in the apoptotic process and/or impaired apoptotic cell removal mechanisms. Among apoptosis-inducing genes, an importantrole is played by p53. In the present study, we have investigated the possible relationship between p53 codon 72 polymorphism and asthma and theinteraction with ACP1, a genetic polymorphism involved in the susceptibility to allergic asthma. We studied 125 asthmatic children and 123 healthysubjects from the Caucasian population of Central Italy. p53 codon 72 and ACP1 polymorphisms were evaluated using a restriction fragment lengthpolymorphism-polymerase chain reaction (RFLP-PCR) method. There is a statistically significant association between p53 codon 72 polymorphismand allergic asthma: Arg/Arg genotype is more represented in asthmatic patients than in controls (P=0.018). This association, however, is presentin subjects with low ACP1 activity A/A and A/B only (P=0.023). The proportion of children with A/A and A/B genotype carrying Arg/Arg genotype issignificantly high in asthmatic children than in controls (OR=1.941, 95% C.I. 1.042-3.628). Our finding could have important clinical implications sincethe subjects with A/A and A/B genotypes of ACP1 carrying Arg/Arg genotype are more susceptible to allergic asthma than Pro/Pro genotype.
-
Targeting BRAF pathway in low-grade serous ovarian cancer
Chiara Perrone,Roberto Angioli,Daniela Luvero,Andrea Giannini,Violante Di Donato,Ilaria Cuccu,Ludovico Muzii,Francesco Raspagliesi,Giorgio Bogani 대한부인종양학회 2024 Journal of Gynecologic Oncology Vol.35 No.4
Mutations in genes encoding for proteins along the RAS-RAF-MEK-ERK pathway havebeen detected in a variety of tumor entities including ovarian carcinomas. In the recentyears, several inhibitors of this pathway have been developed, whose antitumor potential iscurrently being assessed in different clinical trials. Low grade serous ovarian carcinoma, isa rare gynecological tumor which shows favorable overall sur vival, compared to the generalovarian cancer population, but worr ying resistance to conventional chemotherapies. Theclinical behavior of low grade serous ovarian carcinoma reflects the different gene profilecompared to high-grade serous carcinoma: KRAS/BRAF mutations. BRAF inhibitors assingle agents were approved for the treatment of BRAF mutated tumors. Nevertheless, manypatients face progressive disease. The understanding of the mechanisms of resistance toBRAF inhibitors therapy and preclinical studies showing that BRAF and mitogen-activatedprotein kinase kinase (MEK) inhibitors combined therapy delays the onset of resistancecompared to BRAF inhibitor single agent, led to the clinical investigation of combinedtherapy. The aim of this paper is to review the efficacy and safety of the combination of BRAFplus MEK inhibitors on ovarian carcinomas, in particularly focusing on low grade serousovarian carcinoma.
KCI
KISS연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
